Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Pneumococcal polysaccharide vaccination among adults aged 65 years and older, U.S., 1989-2008.

Lu PJ, Nuorti JP.

Am J Prev Med. 2010 Oct;39(4):287-95. doi: 10.1016/j.amepre.2010.06.004.

PMID:
20837278
2.

Uptake of pneumococcal polysaccharide vaccination among working-age adults with underlying medical conditions, United States, 2009.

Lu PJ, Nuorti JP.

Am J Epidemiol. 2012 Apr 15;175(8):827-37. doi: 10.1093/aje/kwr376. Epub 2012 Mar 8.

PMID:
22403807
5.

Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).

Centers for Disease Control and Prevention (CDC).; Advisory Committee on Immunization Practices..

MMWR Morb Mortal Wkly Rep. 2010 Sep 3;59(34):1102-6.

6.

Pneumococcal vaccination coverage among persons ≥65 years--United States, 2013.

O'Halloran AC, Lu PJ, Pilishvili T.

Vaccine. 2015 Oct 13;33(42):5503-6. doi: 10.1016/j.vaccine.2015.09.002. Epub 2015 Sep 13.

PMID:
26372859
7.

Racial/ethnic disparities in influenza and pneumococcal vaccination levels among persons aged > or =65 years--United States, 1989-2001.

Centers for Disease Control and Prevention (CDC)..

MMWR Morb Mortal Wkly Rep. 2003 Oct 10;52(40):958-62.

8.
9.

Declining invasive pneumococcal disease in the U.S. elderly.

McBean AM, Park YT, Caldwell D, Yu X.

Vaccine. 2005 Dec 1;23(48-49):5641-5. Epub 2005 Jul 27.

PMID:
16111788
10.
11.
12.
13.

The epidemiologic evidence underlying recommendations for use of pneumococcal polysaccharide vaccine among American Indian and Alaska Native populations.

Said MA, O'Brien KL, Nuorti JP, Singleton R, Whitney CG, Hennessy TW.

Vaccine. 2011 Jul 26;29(33):5355-62. doi: 10.1016/j.vaccine.2011.05.086. Epub 2011 Jun 12.

PMID:
21664217
14.

Streptococcus pneumoniae colonization among patients with human immunodeficiency virus-1 who had received 23-valent polysaccharide pneumococcal vaccine.

Lo YC, Lauderdale TL, Chang SY, Hsiao CF, Hung CC, Chang SC.

J Microbiol Immunol Infect. 2009 Jun;42(3):234-42.

PMID:
19812857
16.

Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults.

Musher DM, Manof SB, Liss C, McFetridge RD, Marchese RD, Bushnell B, Alvarez F, Painter C, Blum MD, Silber JL.

J Infect Dis. 2010 Feb 15;201(4):516-24. doi: 10.1086/649839.

PMID:
20092407
17.

Determinants of adult vaccination at inner-city health centers: a descriptive study.

Nowalk MP, Zimmerman RK, Tabbarah M, Raymund M, Jewell IK.

BMC Fam Pract. 2006 Jan 10;7:2.

18.

Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, Hadler S, Pilishvili T; Centers for Disease Control and Prevention (CDC)..

MMWR Morb Mortal Wkly Rep. 2014 Sep 19;63(37):822-5.

19.

Pneumococcal vaccination in the emergency department: an assessment of need.

Rudis MI, Stone SC, Goad JA, Lee VW, Chitchyan A, Newton KI.

Ann Emerg Med. 2004 Oct;44(4):386-92.

PMID:
15459621
20.

Hepatitis A vaccination coverage among adults aged 18-49 years in the United States.

Lu PJ, Euler GL, Hennessey KA, Weinbaum CM.

Vaccine. 2009 Feb 25;27(9):1301-5. doi: 10.1016/j.vaccine.2008.12.054. Epub 2009 Jan 20.

PMID:
19162116

Supplemental Content

Support Center